Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
Status:
Unknown status
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, randomized study. Participants will be assigned to A or B
groups with a scale of 1:1 , i.e. infuse study drug followed by Xyntha (group A), or the
alternate sequence (group B). All participants who completed the study will enter the
Prophylactic Therapy Study.